Home / Publications / Pain Research Forum / Papers of the Week / A placebo-controlled, randomized, single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of rimegepant in healthy participants.
A placebo-controlled, randomized, single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of rimegepant in healthy participants.
Authors
Bertz R, Bhardwaj R, Morris BA, Ashbrenner E, Coric V, Croop R
Abstract
Rimegepant is an oral, small molecule calcitonin gene-related peptide receptor antagonist for acute treatment of migraine and migraine prevention.
